Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.42 |
| ▸ | WDR5 | P61964 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939824 | 0.86 | POLB (0.45) | WDR5POLBALDH1A1MAPTHDAC1 | |
| SCHEMBL9939862 | 0.85 | KDM1A (0.41) | KLKB1MAP4K1WDR5POLBKDM1A | |
| SCHEMBL9939936 | 0.84 | ENPP2 (0.36) | WDR5ALDH1A1MAPTTRPV1 | |
| SCHEMBL9939851 | 0.83 | CYP1A2 (0.45) | WDR5 | |
| SCHEMBL9939772 | 0.83 | PPARD (0.39) | WDR5ALDH1A1MAPT | |
| SCHEMBL9939974 | 0.83 | PTGES (0.43) | — | |
| SCHEMBL9939865 | 0.82 | CNR1 (0.36) | KLKB1WDR5ALDH1A1MAPT | |
| SCHEMBL9939842 | 0.82 | HDAC3 (0.39) | WDR5POLBHDAC1ROCK2ROCK1 | |
| SCHEMBL9939978 | 0.82 | SMN1; SMN2 (0.42) | POLBALDH1A1MAPTHDAC1ROCK2 | |
| SCHEMBL9939775 | 0.81 | DRD2 (0.40) | WDR5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | KLKB1 3858/4885MAP4K1 3290/4885WDR5 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.